Successful treatment of liposomal amphotericin B refractory Candida glabrata fungaemia in a patient undergoing a stem cell transplantation

Netherlands Journal of Medicine

Volumn 64, Issue 4, 2006, Pages 127-129

  Veldman, B A J ^a   Verweij, P E ^a   Blijlevens, N M A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Candida glabrata; Candidaemia; Caspofungin; Fungaemia

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BUSULFAN; CASPOFUNGIN; CEFTAZIDIME; CIPROFLOXACIN; CYCLOPHOSPHAMIDE; IDARUBICIN; VALACICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ARTICLE; AUTOPSY; BACTERIAL INFECTION; BLOOD CULTURE; CANDIDA GLABRATA; CANDIDIASIS; CASE REPORT; CAUSE OF DEATH; DRUG EFFICACY; FEMALE; FUNGEMIA; FUNGUS CULTURE; GRAFT VERSUS HOST REACTION; HUMAN; MYELOABLATIVE CONDITIONING; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS INFECTION;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; FEMALE; HUMANS; LIPOSOMES; MIDDLE AGED; PEPTIDES, CYCLIC; STEM CELL TRANSPLANTATION; TREATMENT FAILURE;

EID: 33645915092     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997;24(6):1122-8.
2. Bodey GP, Mardani M, Hanna HA, et al. The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. Am J Med 2002;112(5):380-5.
3. Donnelly JP, Muus P, Schattenberg A, de Witte T, Horrevorts A, de Pauw BE. A scheme for daily monitoring of oral mucositis in allogeneic BMT recipients. Bone Marrow Transplant 1992;9(6):409-13.
4. Ellis M. Preventing microbial translocation in haematological malignancy. Br J Haematol 2004;125(3):282-93.
5. Blijlevens NM, Donnelly JP, de Pauw BE. Mucosal barrier injury: biology, pathology, clinical counterparts and consequences of intensive treatment for haematological malignancy: an overview. Bone Marrow Transplant 2000;25(12):1269-78.
6. Nucci M, Anaissie E. Revisiting the source of candidemia: skin or gut? Clin Infect Dis 2001;33(12):1959-67.
7. Nucci M, Colombo AL. Risk factors for breakthrough candidemia. Eur J Clin Microbiol Infect Dis 2002;21(3):209-11.
8. Wingard JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin Infect Dis 1995;20(1):115-25.
9. Rex JH, Bennett JE, Sugar AM, et al, Candidemia Study Group and the National Institute. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med 1994;331(20):1325-30.
10. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-9.
11. Pfaller MA, Diekema DJ, Messer SA, Hollis Rj, Jones RN. In vitro activities of caspofungin compared with those of fluconazole and itraconazole against 3,959 clinical isolates of Candida spp., including 157 fluconazole-resistant isolates. Antimicrob Agents Chemother 2003;47(3):1068-71.
12. Pfaller MA, Messer SA, Boyken L, et al. Caspofungin activity against clinical isolates of fluconazole-resistant Candida. J Clin Microbiol 2003;41(12):5729-31.
13. Canton E, Peman J, Viudes A, Quindos G, Gobernado M, Espinel-Ingroff A. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 2003;45(3):203-6.
14. Ostrosky-Zeichner L, Oude Lashof AM, Kullberg BJ, Rex JH. Voriconazole salvage treatment ofinvasive candidiasis. Eur J Clin Microbiol Infect Dis 2003;22(11):651-5.
15. Denning DW. Echinocandins: a new class of antifungal. J Antimicrob Chemother 2002;49(6):889-91.
16. Bartizal K, Gill CJ, Abruzzo GK, et al. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743, 872). Antimicrob Agents Chemother 1997;41(11):2326-32.
17. Wout JW, Kuijper EJ, Verweij PE, Kullberg BJ. Nieuwe ontwikkelingen in de antifungale therapie: fluconazole, itraconazole, voriconazole, caspofungin. Ned Tijdschr Geneeskd 2004;148(34):1679-84.